More about

Car T-Cell Therapy

News
December 20, 2022
2 min watch
Save

VIDEO: CAR T-cell access lags for those with relapsed refractory multiple myeloma

VIDEO: CAR T-cell access lags for those with relapsed refractory multiple myeloma

NEW ORLEANS — In this video, Samer Al Hadidi, MD, MS, FACP, discusses an analysis of access to chimeric antigen receptor T-cell therapy presented at the ASH Annual Meeting and Exposition.

News
December 12, 2022
3 min read
Save

Experimental CAR-T safe, ‘highly effective’ for certain patients with T-cell malignancies

Experimental CAR-T safe, ‘highly effective’ for certain patients with T-cell malignancies

NEW ORLEANS — A novel chimeric antigen receptor T-cell therapy conferred a 78% complete response rate in patients with heavily pretreated T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, study results showed.

News
December 08, 2022
10 min listen
Save

Healio Minute Podcast, Hematology Oncology Edition: Top Headlines - Week of December 5, 2022

Healio Minute Podcast, Hematology Oncology Edition: Top Headlines - Week of December 5, 2022

In this edition, fludarabine has been placed on the FDA’s drug shortage list; epcoritamab is approved for advanced lymphoma; pembrolizumab with chemotherapy improves OS in gastric cancer, and more.

News
November 29, 2022
1 min read
Save

FDA roundup: Recent approvals, drugs in the pipeline for lymphoma treatment

The treatment landscape of lymphoma has expanded rapidly within the last year, including recent FDA approvals and new designations of drugs in the pipeline.

News
November 29, 2022
3 min read
Save

Advancements, future research in diffuse large B-cell lymphoma treatment

Advancements, future research in diffuse large B-cell lymphoma treatment

Treatment regimens for diffuse large B-cell lymphoma have seen many recent advancements, thanks in large part to the development of targeted agents.

News
November 23, 2022
4 min read
Save

Fludarabine shortage requires flexibility, alternative approaches for CAR-T and HSCT

Fludarabine shortage requires flexibility, alternative approaches for CAR-T and HSCT

For the second time in the last 2 years, a drug related to the administration of cellular therapy — fludarabine — has been placed on the FDA’s drug shortage list.

News
November 18, 2022
3 min read
Save

CAR-T destined for earlier lines of therapy in blood cancers, experts say

CAR-T destined for earlier lines of therapy in blood cancers, experts say

Despite data on the approach still being accumulated, a panel of experts at Chemotherapy Foundation Symposium predicted that chimeric antigen receptor T cells will become front-line therapy for multiple hematologic malignancies.

News
November 10, 2022
3 min read
Save

CAR-T effective for younger patients with leukemia, regardless of socioeconomic status

CAR-T effective for younger patients with leukemia, regardless of socioeconomic status

Socioeconomic status had no impact on complete remission rates or overall survival among younger patients who received chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia, study results showed.

News
November 08, 2022
3 min read
Save

CAR-T regimen ‘should be new standard’ for high-risk B-cell acute lymphoblastic leukemia

CAR-T regimen ‘should be new standard’ for high-risk B-cell acute lymphoblastic leukemia

Dual administration of CD19- and CD22-directed chimeric antigen receptor T cells conferred a 99% complete remission rate in younger patients with relapsed or high-risk B-cell acute lymphoblastic leukemia, phase 2 study results showed.

News
October 30, 2022
1 min read
Save

Bispecific CAR-T induces response in blood cancers

Bispecific CAR-T induces response in blood cancers

Three-quarters of patients with advanced B-cell malignancies who received an investigational chimeric antigen receptor T-cell therapy achieved complete response, according to the agent’s manufacturer.

View more